Question

Which of the following should be monitored regularly for a patient who is taking a luteinizing hormone-releasing hormone (LHRH) agonist?

A. Bone mineral Density.

B. Echocardiogram.

C. Nuclear medicine bone scan.

D. Positron emission Tomography.

Answer 1

Bone mineral density should be monitored regularly for a patient who is taking a luteinizing hormone releasing agonist becuase risk of decreased bone mineral density is found in such patients causing osteoporosis ,also fractures

Whereas other options are incorrect as they can be used as method to monitor bone mineral density

As option b echocardiogram now found that can be used to detect bone mineral density to diagnose osteoporosis or possible fracture

In same way option c nuclear medicine bone scan can be used to detect bone mineral density in patients taking LHRH agonist to identify risk of osteoporosis and fracture

Option d is totally wrong as Positron emission tomography is not used to check osteoblastic response of tumor cells but used to detect metabolic response of tumor cells ( as LHRH agonist is taken mainly by prostate cancer patient and have high risk of metastasis and due to LHRH agonist toxicity risk of bone fracture and osteoporosis have been found)

Thus correct option is A because what is actually to be monitored regularly is bone mineral density and other are mainly methods which can be used to detect it so that osteoporosis risk or fracture risk can be identified and treated timely

PLEASE UPVOTE IF YOU FIND IT SATISFACTORY.COMMENT IF ANY DOUBT.